Cartalax (AED, Ala-Glu-Asp cartilage peptide bioregulator)
The Ground Truth Score
four plain questions, never one numberCell-culture peptide, no human trials
Bottom line
A Khavinson-school cartilage tripeptide with a plausible epigenetic story and some in-vitro/animal data, but zero controlled human trials and almost no real-world signal, so any joint benefit is currently unproven and easily confused with placebo.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Community/vendor-reported only (NOT prescribed and NOT standardized): typically a 20 mg lyophilized vial reconstituted with bacteriostatic water, dosed subcutaneously once daily in short courses of ~10-20 consecutive days, often repeated quarterly.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No controlled human trial has ever been completed or registered. The molecule was synthesized by the St. Petersburg Institute of Bioregulation and Gerontology around 1999; vendor pages reference Russian "clinical" and "multi-center" use circa 2010-2015, but no protocol, patient count, endpoint, or peer-reviewed human result is published, and there is no ClinicalTrials.gov registration and no FDA/EMA evaluation. The most honest statement is that documented human use exists only as unreplicated Russian observational reports and gray-market self-experimentation.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Synthetic tripeptide (Ala-Glu-Asp / AED) from the Khavinson 'peptide bioregulator' family, positioned as cartilage- and joint-specific.
- Proposed to act epigenetically on chondrocytes to upregulate cartilage matrix genes (collagen II, aggrecan, proteoglycans) and downregulate degradative MMPs.
- In-vitro work reports shifts in senescence/longevity markers (lower p16, p21, p53; higher SIRT6) and effects on fibroblast and cartilage-cell proliferation.
- Marketed for osteoarthritis, joint comfort, and connective-tissue aging, and commonly stacked with other bioregulators such as Epitalon for systemic longevity.
- Reported (Russian-literature) tolerability is high with side effects described as mild and rare.
The data behind each bullet
What actually backs it
Cartalax is the synthetic tripeptide Ala-Glu-Asp (AED), part of the Khavinson short-peptide bioregulator family, derived conceptually from cartilage tissue.
Consistently described across independent references including a Wikipedia entry that gives the formula C12H19N3O8; identity is well-attested even though efficacy is not. Note: it is a TRIpeptide (AED), distinct from the AEDG tetrapeptide Epitalon/Pinealon, which vendor pages frequently conflate.
PubMed: Ala-Glu-Asp peptide literature ↗No controlled human clinical trial of Cartalax has been registered or published; there is no FDA or EMA approval.
No ClinicalTrials.gov record returns for 'Cartalax'; Wikipedia classes it under 'Drugs with no legal status / missing ATC code' and states only limited human studies have been published. This blank is the single most important fact on the page.
ClinicalTrials.gov search: Cartalax ↗The supportive biology is in-vitro and animal-model only: gene-expression/cell-culture changes (e.g., raised IGF1 expression in aging mesenchymal stem cells, matrix-gene modulation) and rodent cartilage/anti-aging models.
Khavinson-group short-peptide publications are predominantly cell-culture and rodent studies; most indexed work is for the related AEDG tetrapeptide, with the AED tripeptide far thinner. Gene-expression in a dish is not a demonstrated tissue, animal, or human outcome.
PubMed: Khavinson peptide gene expression ↗Human efficacy claims (e.g., 20-40% osteoarthritis pain reduction) trace only to unreplicated Russian observational reports, not independent controlled data.
Vendor and aggregator pages attribute pain/mobility improvements to Russian observational use; no independent Western replication or registered trial exists to corroborate. Treat percentages as marketing, not evidence.
PubMed: AED peptide osteoarthritis cartilage ↗Reported safety is mild (mainly injection-site reactions), but there is no Western safety dataset and no long-term human data.
Safety reassurances cite '40 years of Russian clinical use' anecdotally; no controlled adverse-event dataset, pharmacovigilance record, or long-term human follow-up is available in indexed literature.
PubMed: Khavinson peptide safety tolerability ↗Mechanism
How it's assumed to work
Assumed mechanism (not proven in humans): as an ultrashort Khavinson 'peptide bioregulator,' AED is theorized to enter cells, reach the nucleus, and bind specific DNA/regulatory regions to modulate tissue-specific gene expression epigenetically rather than via classical receptor signaling. In cartilage this is proposed to upregulate matrix genes (type II collagen, aggrecan, proteoglycans) and downregulate matrix metalloproteinases, while shifting senescence markers (lower p16/p21/p53, higher SIRT6). Framed as assumed because the DNA-binding/gene-regulation model is largely cell-culture-derived and not validated as a clinical mechanism.
Dosing & handling
What users and clinicians report
Community/vendor-reported only (NOT prescribed and NOT standardized): typically a 20 mg lyophilized vial reconstituted with bacteriostatic water, dosed subcutaneously once daily in short courses of ~10-20 consecutive days, often repeated quarterly. Reported daily amounts vary enormously between sources, from microgram ranges (~100-200 mcg) up to several milligrams, which by itself signals the figures are guessed rather than measured.
There is no validated human dose. The wide, internally inconsistent dosing figures across vendor sites (microgram vs multi-milligram) are a credibility red flag, not a protocol. No regulator has set any dose, and bioavailability/PK numbers cited online are estimates without published human data. Anyone considering it should treat all figures as unverified hearsay.
Timing & food
Reported timing is once daily, often in the evening (some users dose ~30-60 minutes before bed), via subcutaneous injection; food/fasted state is not described as relevant since it is injected, not oral. There is no mechanistic or trial-based reason published for evening dosing, so the timing is convention/anecdote rather than evidence.
Half-life
Not established in humans. Short peptides of this size are expected to be cleared within minutes by peptidases; online figures range from ~30 minutes to ~2-4 hours and are estimates, not measured human pharmacokinetics.
Reconstitution sensitivity
Supplied as a lyophilized powder; reported handling is reconstitution with bacteriostatic water (commonly to ~1 mg/mL), store lyophilized cold (2-8 C, or frozen -20 C for long-term), keep reconstituted product refrigerated at 2-8 C, avoid freeze-thaw cycles, and use within roughly 28 days. As with all peptides, heat, light, and repeated freeze-thaw degrade it; sterile technique matters because it is injected.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Very low. Beyond vendor and SEO/affiliate articles, substantive first-hand community discussion is scarce, essentially a single notable forum thread plus scattered mentions; it is far less discussed than BPC-157 or TB-500.
Consistency
Mixed and vague. The handful of positive anecdotes describe subtle 'joints feel smoother' impressions over weeks; reports are inconsistent, often hedged, and many community threads pivot to recommending other peptides instead.
Source credibility
Low. The information ecosystem is dominated by sellers and affiliate sites with internally contradictory facts (dipeptide vs tripeptide, AED vs AEDG), which means most 'signal' is marketing rather than independent user evidence; genuine unaffiliated testimony is thin.
- Anecdote, not proof: a small number of users report joints feeling smoother or less stiff after finishing a 20 mg vial over several weeks, typically describing the effect as subtle rather than dramatic.
- Sentiment is lukewarm and uncertain; many discussions conclude that better-studied options like BPC-157 (or 'KLOW'-type blends) are a more sensible choice for joint and tissue repair.
- Tolerability is generally described as easy, with little beyond occasional injection-site irritation reported, consistent with the low-toxicity expectation for a tiny peptide.
- A recurring theme is difficulty separating real effect from placebo and from co-administered peptides, lifestyle, or training changes, so even satisfied users tend to hedge their attribution.
Placebo risk, High
Reported benefits (joints feel 'smoother,' less stiff, general comfort) are almost entirely subjective, slow-onset, and measured against fluctuating osteoarthritis symptoms, the classic setup for placebo. There are no objective human endpoints (imaging, cartilage thickness, validated function scores) tied to controlled administration, and the act of injecting daily plus stacking other agents amplifies expectancy effects.
Risk panel
What could go wrong
Adverse events
Most commonly reported (anecdotal / Russian literature) are injection-site reactions: mild redness, swelling, or tenderness. Scattered anecdotes mention transient fatigue or a brief 'flu-like' feeling after early doses and rare mild digestive upset. None of this is from a controlled human safety study.
Theoretical concerns
The proposed mechanism is epigenetic modulation of gene expression (chondrocyte matrix genes, senescence/longevity markers). Any agent claimed to alter gene-expression and cell-proliferation programs carries a theoretical concern about unintended proliferative or off-target tissue effects with chronic use, none of which has been characterized in humans. Sterility/contamination risk from reconstituting and injecting a non-pharmaceutical-grade research product is a real practical hazard.
Contraindications
No formal contraindication list exists because the compound was never through a regulated human program. Prudent caution: active or history of malignancy (given proliferative/epigenetic claims), pregnancy or breastfeeding, and known peptide/excipient allergy. There is no drug-interaction data.
Honest unknowns
Essentially everything load-bearing is unknown in humans: efficacy, effective dose, true pharmacokinetics, long-term safety, oncologic safety of chronic epigenetic signaling, immunogenicity, and product identity/purity from gray-market suppliers. The absence of any registered trial means the risk-benefit ratio cannot honestly be estimated.
Confound watch
Users almost never run it alone. It is commonly stacked with other Khavinson bioregulators (notably Epitalon) and broader joint/recovery agents (BPC-157, TB-500, collagen, glucosamine, NSAIDs), plus training, weight, and load changes. Any perceived joint improvement is heavily confounded by these co-interventions, natural symptom fluctuation in osteoarthritis, and regression to the mean after a flare.
History
Discovery → first use → status
- ~1999AED (Ala-Glu-Asp) tripeptide synthesized by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology as a cartilage-targeted 'bioregulator.'
- 2000sCell-culture and rodent studies from Russian laboratories report matrix-gene modulation, altered senescence markers, and cartilage effects (preclinical only).
- ~2010-2015Vendor histories reference Russian 'clinical' and 'multi-center' use, but no protocol, patient numbers, endpoints, or peer-reviewed human results are published or registered.
- 2020s-2026Sold internationally as a 'research peptide' / gray-market supplement (often 20 mg vials); a Wikipedia entry appears, while community discussion remains sparse and frequently redirects to BPC-157 or other options.
Verification
The COA standard, applied
Cross-checked across a Wikipedia entry, the Khavinson/AED PubMed literature (which is mostly the related AEDG tetrapeptide, confirming how thin the AED-specific human/animal record is), a ClinicalTrials.gov search returning no Cartalax registration, and roughly a dozen vendor/aggregator pages. The convergent finding is no controlled human trial, preclinical-only biology, mild anecdotal safety, and very sparse community signal. Vendor copy is internally contradictory (one source miscalls it a 'dipeptide,' several conflate it with the AEDG tetrapeptide), which lowers source credibility.
The full verification standard →Sources
Where this comes from
- Wikipedia: Cartalax ↗· Confirms AED tripeptide identity (C12H19N3O8), Russian origin, 'anti-aging effects in vitro and in animal models,' only limited human studies, and 'no legal status / missing ATC code.'
- ClinicalTrials.gov search: Cartalax ↗· No registered human trials for Cartalax, corroborating the absent controlled-human-evidence finding.
- PubMed: Ala-Glu-Asp / Khavinson peptide literature ↗· Indexed work is dominated by the related AEDG tetrapeptide (Epitalon) and is preclinical (cell-culture/animal); illustrates how thin the AED-specific human record is.
- PubMed: Khavinson peptide gene expression ↗· Background for the assumed epigenetic/gene-expression mechanism of short Khavinson peptides, demonstrated mainly in vitro.
- PubMed: Khavinson peptide bioregulator safety ↗· Context for safety claims; no controlled human adverse-event dataset specific to Cartalax is indexed.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.